Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Non-infectious fever predicts poor survival in azacitidine-treated high-risk, but not low-risk, myelodysplastic syndromes:a multicenter real-world cohort study (KOTOSG)

Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino et al. Nov 03, 2025 pp. 3850-3850 10.1182/blood-2025-3850

Abstract Background Growing evidence indicates that dysregulated inflammation—marked by specific genetic abnormalities and elevated inflammat...

DNMT3A-driven clonal hematopoiesis permits colitis-associated tumorigenesis by promoting innate immune tolerance

Qingchen Yuan, Yang Feng, Christopher Thai et al. Nov 03, 2025 pp. 3170-3170 10.1182/blood-2025-3170

Abstract Clonal hematopoiesis (CH), defined as an expanded hematopoietic stem cell (HSC) clone with somatic mutations in the absence of bloo...

Clinicopathologic and treatment influences on diffuse large B-cell lymphoma survival: A 10-year safety-net hospital experience

Aye Thida, Erfan Nasirikhaneghah, Lan Chen et al. Nov 03, 2025 pp. 8050-8050 10.1182/blood-2025-8050

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy with outcomes influenced by clinicopathologic facto...

Determinants of early mortality following induction chemotherapy in Acute Myeloid Leukemia: Experience from a comprehensive cancer center in Latin America

Melanie Castro Mollo, Marcos Heredia-Vallejos, Kevin Paez Resalve et al. Nov 03, 2025 pp. 2834-2834 10.1182/blood-2025-2834

Abstract Background: Survival after induction chemotherapy in patients with acute myeloid leukemia (AML) is limited by both treatment-relate...

Son haploinsufficiency in hematopoietic cells disrupts the crosstalk between splicing fidelity and chromatin accessibility, impairing lymphoid lineage commitment

Saeed ZakaKhosravi, Mostafa Mohamed, Amr Elkholy et al. Nov 03, 2025 pp. 3157-3157 10.1182/blood-2025-3157

Abstract Introduction: Hematopoietic lineage specification and differentiation rely on precise gene regulation, integrating transcription fac...

Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study

Yanmin Zhao, Yeqian Zhao, Shanshan Pei et al. Nov 03, 2025 pp. 3404-3404 10.1182/blood-2025-3404

Abstract Venetoclax (VEN) has shown promising efficacy when combined with intensive chemotherapy regimens—such as FLAG-IDA (DiNardo et al. 2...

Abnormal adhesion of particular hematopoietic stem and progenitor cell subpopulations in the bone marrow, driven by aberrant interaction between VCAM-1 and VLA-4, ultimately contributes to leukemogenesis

Tsila Zuckerman, Irina Tikhonova, Maha Agbaria et al. Nov 03, 2025 pp. 1372-1372 10.1182/blood-2025-1372

Abstract Introduction: The interplay between Vascular Cell Adhesion Molecule-1 (VCAM-1) and Very Late Antigen-4 (VLA-4, α4β1 integrin) is es...

Prophylaxis CTLA4-ig reduces anti-AAV neutralizing antibodies in AAV gene therapy for hemophilia

Dandan Yu, Bingqi Xu, Wei Liu et al. Nov 03, 2025 pp. 1293-1293 10.1182/blood-2025-1293

Abstract Objective: This study aimed to investigate the inhibitory effect of CTLA4-Ig on anti-AAV neutralizing antibody (Nab) development af...

Beyond clonal hematopoiesis of indeterminate potential: Understanding how the trisomy 21 context promotes TET2 mutations

Edward Evans, Neetha Paul-Eduthan, Marco De Dominici et al. Nov 03, 2025 pp. 1397-1397 10.1182/blood-2025-1397

Abstract Clonal hematopoiesis of indeterminate potential (CHIP) is the observation in the peripheral blood of a somatic mutation in a gene a...

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

Fabio Andreozzi, Allain Thibeault Ferhat, Anna Maria Raiola et al. Nov 03, 2025 pp. 5980-5980 10.1182/blood-2025-5980

Abstract Background - Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has become an increasingly adopted curative strate...

Real-world utilization patterns of bone-modifying agents for multiple myeloma in the era of novel therapies

Hamlet Gasoyan, Michael Rothberg, Jeffrey Kovach et al. Nov 03, 2025 pp. 4402-4402 10.1182/blood-2025-4402

Abstract Background Little is known about the utilization patterns of bone modifying agents (BMA) among patients with newly diagnosed multip...

Clinical impact of atrial fibrillation on hospitalized patients with myeloproliferative neoplasms: A nationwide analysis

Samhitha Gundakaram, Leen Kayali, Leena Alhusari et al. Nov 03, 2025 pp. 6415-6415 10.1182/blood-2025-6415

Abstract Background: Patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), an...

The prevalence of inborn errors of immunity (IEI)-related gene germline variants and its prognostic impact in Chinese pediatric patients with lymphoma

Caiyan Zhang, Ying Liu, Jing Yang et al. Nov 03, 2025 pp. 5314-5314 10.1182/blood-2025-5314

Abstract Introduction: Patients with inborn errors of immunity (IEI) have a higher risk of developing lymphoma than the general population....

Race matters: Cytopenia trajectories after chimeric antigen receptor T- cell therapy in a single-center study

Sushmitha Nanja Reddy, Anisha Rajavel, Saumya Karne et al. Nov 03, 2025 pp. 4170-4170 10.1182/blood-2025-4170

Abstract CAR T-cell therapy has changed the landscape of relapsed-refractory non-Hodgkin lymphoma and multiple myeloma (MM). While cytokine...

The CHD1L protein regulates cell activation by controlling lipid-related metabolism in B cells

Jun Zeng, Ma Weifeng Nov 03, 2025 pp. 4140-4140 10.1182/blood-2025-4140

Abstract Clinical observation has found that the increase of B-cell infiltration (TIL-B) and the formation of mature tertiary lymphoid struc...

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

Divaya Bhutani, Rajshekhar Chakraborty, Michael Hughes et al. Nov 03, 2025 pp. 579-579 10.1182/blood-2025-579

Abstract Background: MGRS encompasses a group of heterogeneous disorders characterized by renal dysfunction caused by the interaction with a...

A multicentre UK snapshot audit of symptom burden in patients with indolent systemic mastocytosis utilising the ISM-SAF ©

Shyamala Chinnabhandara, Sneha Fernandes, Rory FD Morrice et al. Nov 03, 2025 pp. 7313-7313 10.1182/blood-2025-7313

Abstract Background: Indolent systemic mastocytosis (ISM) is a rare clonal haematological neoplasm driven by KIT D816V mutation in 95% of ca...

Rewiring lipid metabolism: A novel approach to overcome drug resistance in multiple myeloma

Abdullah AlMarzouq, Fatma Necmiye Kaci, Alessio Lepore et al. Nov 03, 2025 pp. 7459-7459 10.1182/blood-2025-7459

Abstract Despite significant therapeutic advancements in multiple myeloma (MM) treatment, which have improved patient outcomes and extended...

Oral decitabine-cedazuridine versus parenteral hypomethylating agents in treatment-Naïve TP53-mutated Myelodysplastic Syndromes

Parth Patel, Michael Canonico, Hayley Hawkins et al. Nov 03, 2025 pp. 7389-7389 10.1182/blood-2025-7389

Abstract Introduction TP53-mutated myelodysplastic syndrome (mTP53-MDS) is characterized by genomic instability, resistance to standard ther...

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

Celine Gregoire, Leila Mohammadnezhad, Ziran Zhao et al. Nov 03, 2025 pp. 1945-1945 10.1182/blood-2025-1945

Abstract Introduction Axicabtagene Ciloleucel (Axi-Cel), a CD28-based anti-CD19 CAR T-cell therapy, induces remission in approximately 50% o...

Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran

Steven Pipe, Tienan Zhu, Kaan Kavakli et al. Nov 03, 2025 pp. 4850-4850 10.1182/blood-2025-4850

Abstract Introduction While the number of approved non-factor hemophilia therapies is increasing, data regarding the perioperative managemen...

Allogeneic hematopoietic cell transplantation in dyskeratosis congenita: Short and long- term outcome of 183 consecutive patients transplanted at EBMT centers

Fabiana Cacace, Filomena Pierri, Francesca Fioredda et al. Nov 03, 2025 pp. 2490-2490 10.1182/blood-2025-2490

Abstract Introduction Dyskeratosis congenita (DKC) is a rare telomere disorder causing multi-organ dysfunction and bone marrow failure, with...

Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Maria Carmen Martinez Munoz, Mathilde Fekom, Anne Huynh et al. Nov 03, 2025 pp. 3620-3620 10.1182/blood-2025-3620

Abstract INTRODUCTION Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma (HL), accounting for appr...

Hematopoietic JAK2V617F mutation increases susceptibility to atrial fibrillation via NLRP3 inflammasome activation in macrophages

Guangshuai Teng, Ke Shang, Yuhui Zhang et al. Nov 03, 2025 pp. 634-634 10.1182/blood-2025-634

Abstract Clonal hematopoiesis of indeterminate potential (CHIP), an age-related phenomenon, elevates the risk of hematological malignancies...

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

Huanxin Zhang, Yi Wang, Chengcheng Fu et al. Nov 03, 2025 pp. 2270-2270 10.1182/blood-2025-2270

Abstract Introduction Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in the treatment of relapsed or refractory (R...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page